Study S000346

A Multicentre, Prospective, Non-Interventional, Single-Arm Study Investigating Glycaemic Control and Patient-Reported Outcomes in Type 2 Diabetes Patients, Uncontrolled on DPP4i Treatment and Who Switch to Oral Semaglutide in a Real-World Setting in Italy

ClinicalTrials.gov record

Registration

Registration: NCT05755360
Acronym: DOORS
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 291
Start: 2023-02-21
Primary completion: 2024-10-21
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1274-4674

Registered primary outcomes

Absolute change in glycated haemoglobin (HbA1c) (percentage [%]-point) [From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)]
Absolute change in glycated haemoglobin (HbA1c) (millimoles per mole [mmol/mol]) [From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.